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Abstract Understanding the interaction of Yersinia pestis with 
the key components of the immune system is important for eluci- 
dation of the pathogenesis of bubonic plague, one of the most 
severe and acute bacterial diseases. Here we report the specific, 
high affinity binding (K d = 1.40 x 10 -1° M + 0.14 x 10 -1°) of ra- 
diolabelled human interleukin 1/3 (hlL-liB) to E. coli cells carry- 
ing the capsular f l  operon of Y. pestis. CarlA outer membrane 
usher protein was isolated to greater than 98% purity. Competi- 
tion studies with purified CaflA, together with immunoblotting 
studies, identified CarlA as the hIL-l~ receptor. Competition 
between Carl subunit and hIL-11] for the same or an overlapping 
binding site on CarlA was demonstrated. Relevance of these 
results to the pathogenesis of Y. pestis and other Gram negative 
bacterial pathogens with homologous outer membrane usher pro- 
teins is discussed. 
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Capsule 
the Cafl subunit [8]. Similarly, Caf lA shares 26% amino acid 
identity with the outer membrane usher protein PapC [12], is 
required for surface localisation of the Cafl subunit [9] and 
belongs to the family of outer membrane usher (chaperone) 
proteins [14]. 
As a result of a computer search of the PIR protein sequence 
library, we have recently identified a statistically significant 
level of similarity between the Cafl subunit and the interleukins 
(ILs)-lc~, fl, ra (receptor antagonist), central cytokines of the 
immune system [15]. Interestingly, it had previously been re- 
ported that IL-1 could bind specifically to virulent but not to 
avirulent strains of Escherichia coli and that this binding led to 
enhancement of bacterial growth [16]. Because of the apparent 
structural similarity of Cafl and the interleukins we therefore 
investigated the ability ofhIL- l f l  to bind to E. coli cells express- 
ing the Cafl operon. In this report we not only demonstrate 
specific binding of hIL-lfl to these cells, but also identify for 
the first time a bacterial protein which exhibits high affinity 
binding for interleukin. 
I. Introduction 
As early as 1894, it was known that the causative agent of 
plague, Yersiniapestis, is capable of forming a large capsule [1]. 
A major component of the capsule is the F1 (fraction 1) antigen 
- a polypeptide of 15.6 kDa, encoded by the f l  operon [2,3]. 
The F1 antigen is highly immunogenic and has attracted most 
attention as a diagnostic tool [4] and component of protective 
vaccine [5]. Although the capsule has been implicated as a 
virulence factor, possibly by conferring resistance to phagocytic 
cells, its importance and role in the pathogenesis of this organ- 
ism is not clear and appears to depend on the animal model 
[6,7]. 
Recently, the f l  operon was cloned from the 110 kb (Fral)  
plasmid of Y. pestis. It consists of four genes responsible for the 
synthesis and surface assembly of F1 capsule cafl, caflM, 
caflA and caflR encoding, respectively, the capsular protein 
Cafl [3], Caf lM (capsule antigen F1 mediator) [8], Caf lA (cap- 
sule antigen F1 assembly) [9] and a DNA-binding transcrip- 
tional regulator Cafl R [10]. Thef l  operon is one of the simplest 
members of a widespread family of surface assembly related 
operons the prototype model of which is the pap operon in- 
volved in Pap pili assembly in uropathogenic E. coli [11-14]. 
Thus, Caf lM shares 26% identity and 54% amino acid sequence 
similarity with the periplasmic haperone, PapD and as with 
PapD stabilises the periplasmic intermediate - in this case of 
*Corresponding author. Fax: (7) (095) 5461574. 
2. Materials and methods 
2.1. Bacterial strains, plasmids and culture conditions 
For all experiments E. coil HB101 or DH5cx [17] carrying the appro- 
priate plasmid was grown at 37°C in LB broth containing ampicillin 
(100 pg/ml). Plasmid p l2R [8] has been described. For overexpression 
ofcaflM, the caflMgene was isolated on a 0.8 kb BspHI-SmaI DNA 
fragment from pl2R and ligated into NcoI-HpaI digested pTrc99a 
vector (Pharmacia) to give pTCA1. The cafl gene was amplified by 
PCR from pl2R using primers 5' CTGCAGGGTTATCCACAACC- 
TGCATC and 5' CTGCAGCGAGGGTTAGGCTCAAAGTA which 
are complementary to regions 112-93 bp upstream from the start codon 
and 8 37 bp downstream from the transcription terminator of cafl, 
respectively. The 720 bp amplified fragment was subcloned into 
pGEM-T vector (Promega) and the DNA sequence verified. Using the 
unique PstI sites designed in the primers, the correct cafl gene was then 
isolated on a PstI fragment and inserted into a unique PstI site 79 bp 
downstream from the end of caflM in pTCA1. Correct orientation of 
cafl in this final construct (pFM 1) was verified by restriction analyses. 
All DNA manipulations were performed according to standard proce- 
dures [17]). Cultures ofE. coli DH5a carrying either pTCA1 or pFM1 
were maintained in the presence of 0.2% glucose. 
2.2. Kinetics of lL-l~ binding 
Recombinant hIL-lfl was purified as described by Mashko et al. [18] 
and iodinated using the chloramine-T method [19] to a specific activity 
of 80 Ci/mole. 16 to 18 h cultures of HB101/pl2R were washed in LB 
and resuspended in 50 mM Tris-HCl pH 7.2, 150 mM NaCI containing 
1 mM PMSF (TSP-buffer). Binding experiments were performed in 
triplicate at 0°C for 1 h with 5 x 105 cells in a final volume of 1 ml. For 
the analysis of specific binding, the cells were incubated with radiola- 
belled hIL-lfl (concentration range from 10-12 to 10-SM). Specific bind- 
ing was defined as that inhibited by 1 /~M unlabelled hIL-lfl. The 
incubation was terminated by rapid filtration through GF/B glass fiber 
filters (Whatman) under vacuum pressure. Filters were rinsed twice 
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with 5 ml volumes of ice-cold TSP-buffer. Radioactivity was measured 
with a Mini Gamma Counter (LKB). 
2.3. Immunoblotting 
(i) Binding ofhlL-l~. Cells of 1(~18 h cultures of E. coli HB101 
carrying p12R or pUC 19 were harvested by centrifugation a d solubil- 
ised in Laemmli's ample buffer at 100°C. Samples (containing 10 mg 
protein) were resolved by SDS-PAGE and electroblotted to nitrocellu- 
lose membrane for 18 h at 150 mA. Non-specific binding sites were 
blocked by incubation in 10 mM Tris-HC1 pH 7.5, 150 mM NaC1, 2% 
bovine serum albumin, 0.05% Tween 20 (blocking buffer) for 18 h at 
4°C. Blots were then incubated for 1 h at 37°C in blocking buffer 
containing hIL-lfl (10/tg/ml), washed three times with blocking buffer, 
incubated 1h with horseradish peroxidase-conjugated rabbit anti-hIL- 
lfl immunoglobulin G in blocking buffer. Following three additional 
washes blots were developed using 1.3 M diaminobenzidine and 0.2% 
H202 in 10 mM Tris-HC1 pH 7.4, 150 mM NaC1. Biotinylated markers 
were stained with peroxidase-conjugated avi in (Sigma). 
(ii) Identification of CaflM. A synthetic peptide corresponding to
residues 135-150 of CaflM [8] i.e. the additional loop in comparison 
with the known periplasmic molecular chaperones [8,11] was synthe- 
sized by the semi-automatic continuous-flow solid phase method [20]. 
Polyclonal antisera was obtained from mice immunised with the peptide 
coupled to keyhole limpet hemocyanin with glutaraldehyde. Samples 
were subjected to SDS-PAGE, transferred to nitrocellulose membrane 
and developed as described above using mouse anti-CaflM peptide 
serum (11500 dilution) and antimouse IgG peroxidase conjugate as the 
first and second antibodies, respectively. 
2.4. Purification of CaflA (p90) 
Bacterial cells harvested from 300 ml of a 16 h culture of E. coli 
HB101/pl2R were resuspended in 3 volumes TS buffer (10 mM Tris- 
HCI pH 7.5, 150 mM NaC1) containing 5 mM EDTA and 0.1 mM 
PMSF and disrupted on ice by four cycles of sonication (30 s with 
Labsonic 2000 homogenizer at20 kHz with 60 s cooling). After centrif- 
ugation at 15,000 × g for 30 rain, the pellet was resuspended in 1.5 
volume TS buffer with 5 mM EDTA and 0.1 mM PMSF, homogenized 
and centrifuged as before. The pooled supernatants (4.5 ml, 4 mg total 
protein) were fractionated by gel-filtration chromatography on a 
TOYOPEARL HW-55 (1 × 70 cm) column in TS buffer, containing 
5 mM EDTA. The column was calibrated with markers from Pharma- 
cia (ribonuclease A, 13.7 kDa; chymotrypsinogen A, 25 kDa; ovalbu- 
min, 43 kDa; bovine serum albumin, 66 kDa; aldolase-158 kDa and 
catalase, 232 kDa). Fractions containing IL-lfl-binding activity (90 
160 kDa region; 360/zg protein) were precipitated with ammonium 
sulphate (45 g/100 ml), and the resulting precipitate recovered by cen- 
trifugation (27,000 x g, 30 min) and dissolved in TS-buffer. This prepa- 
ration (250 pg protein) was dialyzed against TS-buffer and further 
fractionated by chromatography ona MonoQ column with a Pharma- 
cia FPLC system. Following elution with a 0.15q3.5 M NaC1 gradient 
in 20 mM Tris-HCl buffer pH 7.2 (A-buffer), p90 was identified in 
fractions containing 150 mM NaC1. Pooled fractions (75/zg protein) 
were diluted sixfold with A buffer and re-fractionated bychromatogra- 
phy on a MonoQ column. Fractions containing p90 were pooled (37 
/zg protein). 
2.5. Interleukin-l~ plate binding assay 
Samples of fractions from Gel-filtration or ion exchange chromatog- 
raphy were diluted to 5/lg per ml with TS-buffer. Fifty ml of the diluted 
samples were allowed to adhere to mierotiter wells (Dyneteck) over- 
night at 4°C. After blocking the wells with 200/~1 of blocking buffer, 
wells were sequentially incubated for 1 h each with 100/~1 of blocking 
buffer containing 1 /zg/ml hIL-lfl, followed by rabbit antiserum 
(115000), and finally anti-rabbit IgG conjugated to peroxidase. Between 
successive incubations the wells were rinsed four times with TS-buffer 
containing 0.05% Tween 20. The assays were read on Titertek Multi- 
skan (Flow) after incubation with 0.4 mM 3,3'5,5'-tetramethylbenzid- 
ine per ml in 10 m1100 mM Na acetate buffer pH 5.0 containing 0.004% 
H202 (v/v). 
2.6. Purification of Cafl M chaperone and chaperone-subunit complex 
Following induction of exponentially growing cells (OD600 = 0.4-0.5) 
with 1 mM IPTG for 2 h, E. coli DH5cdpTCA1 and E. coli DH5c~/ 
pFMI possess high levels of periplasmic haperone and chaperone 
complex, respectively. The periplasmic fraction was isolated from such 
cultures by osmotic shock. Cells from 500 ml culture were suspended 
in 5 ml 20% (w/v) sucrose, 20 mM Tris-HC1 pH 8.0, 5 mM EDTA at 
20°C. After 5 min cells were removed by centrifugation and resus- 
pended in cold 10 mM MgC12 and incubated on ice for 5 rain. CaflM 
or complex were recovered in the supernatant fraction (periplasmic 
fraction) following further centrifugation. To recover CaflM, the 
periplasmic fraction was diluted tenfold with A buffer to 0.2 0.3 mg 
total protein per ml and fractionated on a MonoQ column with a 
Pharmacia FPLC system. Unbound fractions were precipitated with 
ammonium sulphate (37.5 g/100 ml), and the resulting precipitate con- 
taining CaflM was recovered by centrifugation (27,000 × g, 30 rain). 
The pellet containing CaflM was dissolved in A-buffer and fractionated 
on a Superose 12 HR 10130 column. CaflM was eluted with a molecular 
weight of approximately 29 kDa. 
To recover CaflM Carl complex, the periplasmic fraction was di- 
luted with TS-buffer to 1 mg total protein per ml and fractionated on 
a MonoQ column. Following elution with 0.15-0.8 M NaC1 in A buffer, 
the CaflM-Cafl complex was identified in a fraction containing 0.24 M 
NaCI. 
For affinity chromatography of CaflM-Cafl complex, an anti-Carl 
IgG-sepharose affinity column was prepared as described [21]. A sam- 
ple (20 ~tg protein in 0.5 ml A-buffer containing 0.24 M NaCI) of 
CaflM-Cafl complex eluted from the MonoQ column was applied to 
the affÉnity column (0.5 ml). The column was washed with 10 ml 
A-buffer containing 0.5 M NaC1 and 5 ml A-buffer and bound proteins 
were eluted with 0.01 M acetic 
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Fig. 1. (a) Scatchard analysis for [~25I]hlL-lfl binding to E. coli HB101/ 
pl2R. (b) Immunoblot of binding of hlL-lfl to a 90 kDa polypeptide 
in E. coli HB101/pl2R. Lanes: (1) E. coli HB101/pl2R; (2) E. coli 
HB101/pUC 19. 
additional genes - those responsible for expression of the pre- 
Cafl (17.6 kDa), preCaflM (28.8 kDa), preCaflA (93.6 kDa) 
and CaflR (36 kDa) proteins [3,8-10]. Thus the outer mem- 
brane usher protein, CaflA (mature polypeptide, putative 
M, -- 90.4) appeared to represent an obvious candidate as re- 
ceptor for specific binding of hIL- lfl to E. coli cells expressing 
the f l  operon. The CaflA protein (p90) was isolated from 
recombinant E. coli strain HB101/pl2R by a protocol involving 
disruption of cells/release of CaflA by sonication followed by 
gel-filtration and ion exchange chromatography of the superna- 
tant fraction, as described in section 2. Throughout the purifi- 
cation procedure samples from different fractions were analy- 
sed for IL-lfl binding activity as well as for protein concentra- 
tion and by sodium dodecylsulfate-polyacrylamide gel electro- 
phoresis (SDS-PAGE). Fractions containing IL-lfl binding 
activity were eluted from the Toyopearl HW-55 column in the 
90-160 kDa region (not shown). The final preparation of 
CaflA was greater than 98% pure as judged by SDS-PAGE 
(Fig. 2a). In control experiments using similar fractions ob- 
tained from E. coli HB101/pUC19 no IL-lfl activity could be 
detected. It can be seen from Fig. 2b that purified CaflA effec- 
tively inhibited [125I]IL-lfl binding to HB10I/pl2R cells 
(g  i = 2 x 10 -1° M). 
Genetic structures, similar in organisation and function to 
the f /  operon, have been found in many pathogenic Gram- 
negative bacteria (Bordetella pertussis, Klebsiella pneumoniae, 
Haemophilis influenzae, Salmonella typhimurium, E. coli 
[11-14]. Each of these operons encode an outer membrane 
usher protein which facilitates urface localisation and correct 
assembly of virulence-associated surface organelles (capsules, 
pili, fimbriae). Porat et al. [16] have found that IL-1 displays 
reactivity with virulent E. coli strains and increases the number 
of colony-forming entities. It was proposed that human IL-1 
may recognize a functional IL-l-like receptor structure on vir- 
ulent E. coli and may be a virulence factor for bacterial patho- 
genicity. In accordance with the data reported here a candidate 
for the receptor molecules for IL-1 on the surface of pathogenic 
strains of E. coli are the outer membrane molecular usher 
proteins involved in fimbriae/non-fimbrial adhesin assembly. 
3.3. Competition between Cafl and hlL-l~ for binding to CaflA 
The CaflA protein acts as an anchor to attach the Cafl 
capsule to the outer membrane as well as an usher during 
export across the outer membrane [9]. It was, therefore, also 
important to ascertain the ability of Cafl to compete for the 
IL-lfl binding sites. Purified Cafl protein is in a polymerized 
form (MW more than 106). Thus, it was not possible to test this 
form of Call in competition experiments. The molecular 
chaperone, CaflM, however, protects Cafl from polymerisa- 
tion. The capsular subunit-chaperone complex was, therefore, 
purified from E. coli HB101/pFM1 by osmotic shock and ion 
exchange chromatography (Experimental procedures) and 
tested in competition experiments. To confirm that the test 
fraction actually contained a Cafl-Cafl M complex rather than 
the free proteins, a sample of the test fraction was passed 
through an anti-Call IgG-Sepharose affinity column. Fig. 3a 
and b show the results of SDS-PAGE and immunoblot analy- 
ses, respectively, of the bound and subsequently eluted protein 
complex. It can be seen from Fig. 3c that the Cafl-CaflM 
complex effectively inhibited [~25I]hlL-lfl binding to E. coli 
HB101/pl2R cells (K i = 5 x 10 -1° M). No inhibition of [125I]IL- 
lfl binding by free CaflM was observed (Ki > 10-6). To exclude 
the possibility that Cafl and hlL-lfl might copolymerise as a 
consequence of the homology of their structures [15], we inves- 
tigated the interaction of hlL-lfl with immobilised Cafl by 
ELISA. No specific binding of hlL-lfl to Cafl was observed. 
These data suggest that hlL-lfl and Cafl compete for a com- 
mon binding site on the outer membrane usher protein, CaflA. 
It has been reported that some Gram-negative bacteria pro- 
duce a protein with IL-l-like activities [16]. We found that in 
a search of the PIR protein sequence library, Cafl shared the 
highest level of homology with hIL-lra (28% identity between 
aa 62 89 of Cafl and aa 57-85 of hIL-lra) [15]. Subsequent 
alignment with other members of the IL-l-like superfamily of 
proteins revealed further significant homologies [15]. Thus, of 
18 hydrophobic positions forming a hydrophobic core in all the 
previously studied proteins with the IL-l-like conformation 
[22], 15 positions are also occupied by hydrophobic residues in 
the Cafl protein. All these residues are located in fl-pleated 
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Fig. 2. (a) SDS-PAGE of purified p90 protein (CaflA) isolated from 
recombinant E. coli strain HB101/pI2R. (b) Concentration-dependent 
inhibition of [125i]hlL. lfl binding to E. coil HB 101/p 12R by p90 protein 
(CaflA). 
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Fig. 3. (a) SDS-PAGE of the purified Cafl-CaflM complex isolated 
from recombinant E, coli strain DH5/pFMI. (b) Immunoblot analysis 
of proteins cluted from affinity anti-Cafl IgG-Sepharose column. (c) 
Concentration-dependent inhibition of [~25I]hIL-lfl binding to E. coli 
HB101/pl2R by the purified Cafl-CaflM complex. 
sheets forming the hydrophobic ore in the IL-l-like proteins 
[22]. Moreover, of 10 homologous positions occupied by hydro- 
philic residues located on the surface of hi L- I a,,8, ra molecules, 
7 positions are conserved in the Cafl protein. Arg-18, Glu-25, 
Asp-78, Asp-97, Glu-105, Ser-125 and Thr-145 in the Call 
sequence correspond, respectively, to Arg-4, Asp-12, Asp-75, 
Glu-96, Glu-105, Thr-124 and Thr-144 in the hlL-lf l sequence. 
Importance of some of these conservative r sidues to the func- 
tion of hlL-1/~ has been demonstrated by site-directed mut- 
agenesis [23]. Mutation of Arg-4, Asp-12 or Glu-105 had a 
dramatic effect on the activity of hlL-lfl, including its receptor 
binding capacity; mutations of Asp-75, Glu-96, Thr-124 and 
Thr-144 had only a limited effect. A similar dramatic effect was 
induced by replacement of Lys-93 with methionine in hlL-lfl; 
whereas ubstitution with arginine did not reduce the receptor 
binding activity of hlL-lf l [23]. Arg-94 of the Call  sequence 
corresponds to Lys-93 in the primary structure of hlL-lfl [15]. 
These data are in accord with the competition studies and 
support he hypothesis that the Cafl protein and hlL-lf l are 
competing for the identical or overlapping binding sites of p90 
(CaflA) molecule. 
The biological significance of these results to Y. pestis infec- 
tion have yet to be clarified, however, possible ramifications to 
the pathogenesis of this organism are numerous. Competition 
of Cafl with hlLs- la,  fl, ra for binding to the hlL-1 receptor 
on human lymphoid cells is one implication of the above data. 
The ability of viruses to elude the host's defense system by 
releasing soluble receptors for a number of key regulatory com- 
ponents of the immune system, including IL-lfl receptor [24], 
has recently attracted much attention [25]. While viruses appear to 
use genes 'stolen' from their host to achieve this, we have shown 
here that Y. pestis expresses its own hlL-1 receptor in the outer 
membrane. This membrane bound bacterial receptor may like 
the soluble viral receptors function to intercept hlL-1 - a key 
macrophage signal for inflammation and the adaptive immune 
reponse. In addition, Cal lA  may also have the ability to medi- 
ate attachment of Y pestis to human macrophage via the mem- 
brane anchored hprolL-1 [26] at some crucial stage during the 
infection process. These proposed mechanisms together with 
previously identified virulence determinants of Yersiniae 
[27,28] are likely to represent multiple independent mechanisms 
of Y pestis pathogenesis and only in their orchestration can 
they ensure the extreme virulence of Y. pestis for man. 
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